STAT23h
Sanofi is warned by the FDA over ‘significant’ problems at a key manufacturing plant
The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...
The Pharma Letter7h
FDA sends Sanofi warning letter over quality violations
The FDA issues a warning letter to Sanofi over manufacturing violations at its Massachusetts site, citing contamination and ...
STAT5h
Pharmalittle: We’re reading about a cancer therapy’s gold rush, FDA warning Sanofi, and more news
A Belgian court dismissed a lawsuit against EU chief Ursula von der Leyen centered on text messages she exchanged with Pfizer ...
Sanofi Announces Expanded Marketing Authorization For Sarclisa In The EU - Quick Facts
Sanofi (SNYNF, SNY) said the EU has approved Sarclisa in combination with a standard-of-care regimen, bortezomib, lenalidomide, and ...
Sanofi gets EU approval for Sarclisa for newly diagnosed patients
Sanofi (NASDAQ:SNY) has received EU regulatory approval for its drug Sarclisa for the treatment of newly diagnosed multiple myeloma patients. The drug was approved for use in combination with a ...
The Pharma Letter8h
Sarclisa gains European nod for first-line multiple myeloma
Sanofi secures EU approval for Sarclisa with VRd for newly diagnosed multiple myeloma patients ineligible for stem cell ...
Indiatimes21h
Sanofi India Share Price
Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 12,424.21 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...